Why MannKind (MNKD) Stock Is Up Today

NEW YORK (TheStreet) -- MannKind  (MNKD) rose Wednesday after Piper Jaffray upgraded the stock to "neutral" from "underweight" and set a $6.50 price target.

The firm noted the company had a positive FDA panel and the valuation is more attractive ahead of the July 15 Prescription Drug User Fee Act date.

The stock was up 9.88% to $7.23 at 10:38 a.m.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNKD Chart

MNKD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind